title: Quality of life in a randomized control trial? Comments concerning MA 17.
authors.forename: Pascale
authors.initials: P
authors.lastname: This
authors.forename: Anne
authors.initials: A
authors.lastname: de la Rochefordière
authors.forename: Anne
authors.initials: A
authors.lastname: Bredart
authors.forename: Bernard
authors.initials: B
authors.lastname: Asselain
authors.forename: Rollon
authors.initials: R
authors.lastname: Poinsot
authors.forename: Sylvie
authors.initials: S
authors.lastname: Dolbeault
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sigal-Zafrani
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015982:Bias; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D015986:Confounding Factors, Epidemiologic; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D000077289:Letrozole; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D009570:Nitriles / Q000627:therapeutic use*; D010349:Patient Compliance; D010352:Patient Dropouts; D017698:Postmenopause; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D011795:Surveys and Questionnaires; D016019:Survival Analysis; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole